Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).

Published on Jul 22, 2019in ACS Medicinal Chemistry Letters3.975
· DOI :10.1021/ACSMEDCHEMLETT.9B00254
Katie E. Archer4
Estimated H-index: 4
(ImmunoGen, Inc.),
Emily E. Reid4
Estimated H-index: 4
(ImmunoGen, Inc.)
+ 12 AuthorsMichael L. Miller17
Estimated H-index: 17
(ImmunoGen, Inc.)
Sources
Abstract
Indolinobenzodiazepine DNA alkylators (IGNs) are the cytotoxic payloads in antibody–drug conjugates (ADCs) currently undergoing Phase I clinical evaluation (IMGN779, IMGN632, and TAK164). These ADCs possess linkers that have been incorporated into a central substituted phenyl spacer. Here, we present an alternative strategy for the IGNs, linking through a carbamate at the readily available N-10 amine present in the monoimine containing dimer. As a result, we have designed a series of N-10 linked IGN ADCs with a wide range of in vitro potency and tolerability, which may allow us to better match an IGN with a particular target based on the potential dosing needs.
📖 Papers frequently viewed together
2 Citations
6 Citations
References0
Newest
Cited By2
Newest
#1Nathaniel R. Wilson (University of Texas Health Science Center at Houston)H-Index: 4
#2Marina Konopleva (University of Texas MD Anderson Cancer Center)H-Index: 106
Last. Naveen Pemmaraju (University of Texas MD Anderson Cancer Center)H-Index: 48
view all 0 authors...
Abstract null Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from the aberrant transformation of plasmacytoid dendritic cells (pDCs) and involving skin, bone marrow, lymph nodes, and central nervous system. Characteristically unique from other myeloid neoplasms, BPDCN cells express CD4, CD56, and CD123 as well as TCL-1 and TCF4 in almost all cases. Historically, this malignancy has exhibited a poor prognosis, with median survival of less than two ye...
Source
#1Dong Yang (Sichuan University)H-Index: 1
#2Jingqi Shi (Sichuan University)
Last. Ziyuan Li (Sichuan University)H-Index: 11
view all 7 authors...
Employing sulfonyl azide as a nitrogen donor, a visible-light-enabled aerobic dealkylative imidation of tertiary and secondary amines involving C(sp3)–C(sp3) bond cleavage with moderate to excellent yields at room temperature is described. It has been demonstrated that this imidation could take place spontaneously upon visible-light irradiation, and could be facilitated considerably by a ruthenium photocatalyst and oxygen. An alternative mechanism to the previous aerobic photoredox pathway has a...
Source
Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of various cancers. Besides a number of approved drugs already on the market, there is a formidable follow-up of ADC candidates in clinical development. While selection of the appropriate antibody (A) and drug payload (D) is dictated by the pharmacolo...
Source
#1Reza Taheri-Ledari (IUST: Iran University of Science and Technology)H-Index: 16
#2Ali Maleki (IUST: Iran University of Science and Technology)H-Index: 57
Last. Ramin FazelH-Index: 1
view all 7 authors...
Abstract Herein, a novel heterogeneous nanoscale reducing agent for antibody cleavage, made of iron oxide nanoparticles, silica network, palladium on calcium carbonate (10%), and dithiothreitol (Fe3O4@Pd/CaCO3-DTT), is presented as a substantial alternative for traditional homogeneous analogues. Conventionally, antibody fragmentation is accomplished using reducing agents and proteases that digest or cleave certain portions of the immunoglobulin protein structure to provide active thiol sites for...
25 CitationsSource